KMID : 1140120050100010034
|
|
Cancer Prevention Research 2005 Volume.10 No. 1 p.34 ~ p.47
|
|
Effects of Hepatic Disease on Flow-limited Verapamil Pharmacokinetics in the DMN-induced Hepatic Cirrhotic Rats
|
|
Hong Jung-Wook
Park Yun-Young Yuan Hai-Dan Kim Hyun-Jin Lee Joo-Won Jhee Ok-Hwa Om Ae-Son Lee Sang-Koo Lee Yun-Sik Shin In-Chul Lee Min-Ho Kang Ju-Seop
|
|
Abstract
|
|
|
The purpose of this study was to determine the effect of hepatic disease severities on pharmacokinetics of flow-limited verapamil in dimethylnitrosamine (DMN)-induced cirrhotic rats. Hepatic cirrhotic rats (SD rats, 200¡250 g) were induced by intraperitoneal injection with 1% DMN solution at a dose of 10¥ìg/g by 3 days/week as experimental groups and same dose of saline as control for 4 weeks. The serum verapamil concentrations were quantified at zero, 10 min, 30 min, 1, 2 and 3 hrs after bolus injection of 3 mg/kg of verapamil by a column-switching HPLC method and pharmacokinetic parameters such as Co, MRT, AUC, Vdss, t1/2 (¥â) and CLp were determined in each group. And then some hepatic tissue was obtained and subjected to analysis of the hepatic 4-hydroxyproline content and were inspected by light microscope after hematoxylin and eosin staining. The serum concentrations and pharmacokinetic parameters such as Co, AUC, MRT and t1/2 (¥â) were significantly increased (p£¼0.01) and Vdss and CLp were significantly decreased (p£¼0.01) in hepatic cirrhotic rats according to DMN-treated period. The 4-hydroxyproline content was also gradually increased propertionally to DMN-treated period. The pharmacokinetic parameters of verapamil were seemed to change gradually to depend on the hepatic fibrotic severity. Therefore, we suggested that flow-limited drug as like verapamil dosage adjustment is necessary according to hepatic function severity. (Cancer Prev Res 10, 34-47, 2005)
|
|
KEYWORD
|
|
Flow-limited Verapamil, Cirrhosis, HPLC, Pharmacokinetic Parameter
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|